ICAM1 Gene Malaria Cerebral Susceptibility to Genetic Test
At DNA Labs UAE, we offer a comprehensive genetic test for ICAM1 gene malaria cerebral susceptibility. This test can provide valuable insights into an individual’s risk of developing cerebral malaria, a severe form of the disease that affects the brain.
Test Details
The ICAM1 gene is involved in the immune response and plays a role in various diseases, including malaria. Malaria is a mosquito-borne infectious disease caused by the Plasmodium parasite. It primarily affects red blood cells and can lead to severe complications, including cerebral malaria.
Cerebral malaria is a severe form of the disease that affects the brain and can result in coma, seizures, and death. The ICAM1 gene has been found to be associated with susceptibility to cerebral malaria. Variations in this gene can affect the expression or function of ICAM1, potentially influencing the immune response to the Plasmodium parasite and the development of cerebral malaria.
Test Components and Price
The ICAM1 gene malaria cerebral susceptibility genetic test is priced at 4400.0 AED. The test can be performed using blood or extracted DNA samples, or even just one drop of blood on an FTA card.
Report Delivery and Method
The report for the ICAM1 gene malaria cerebral susceptibility genetic test is typically delivered within 3 to 4 weeks. The test is conducted using NGS (Next-Generation Sequencing) technology, which is a powerful tool for analyzing an individual’s DNA sequence.
Test Type and Doctor
The ICAM1 gene malaria cerebral susceptibility genetic test falls under the category of Osteology Dermatology Immunology Disorders. This test is conducted by our experienced dermatologists in the Genetics department.
Pre Test Information
Prior to undergoing the ICAM1 gene malaria cerebral susceptibility genetic test, it is important to provide the clinical history of the patient. Additionally, a genetic counseling session may be conducted to draw a pedigree chart of family members affected by the ICAM1 gene malaria cerebral susceptibility genetic test.
Significance of the Test
NGS genetic testing for ICAM1 gene variants associated with malaria susceptibility can provide valuable information for understanding an individual’s risk of developing cerebral malaria. This information can be used to guide preventive measures, such as mosquito bite prevention strategies or targeted interventions, to reduce the risk of developing severe complications from malaria.
It is important to note that genetic testing for malaria susceptibility is not typically performed as a routine diagnostic test. It is primarily used in research settings to study the genetic factors underlying disease susceptibility and to develop new strategies for prevention and treatment.
| Test Name | ICAM1 Gene Malaria cerebral susceptibility to Genetic Test |
|---|---|
| Components | |
| Price | 4400.0 AED |
| Sample Condition | Blood or Extracted DNA or One drop Blood on FTA Card |
| Report Delivery | 3 to 4 Weeks |
| Method | NGS Technology |
| Test type | Osteology Dermatology Immunology Disorders |
| Doctor | Dermatologist |
| Test Department: | Genetics |
| Pre Test Information | Clinical History of Patient who is going for ICAM1 Gene Malaria, cerebral, susceptibility to NGS Genetic DNA Test. A Genetic Counselling session to draw a pedigree chart of family members affected with ICAM1 Gene Malaria, cerebral, susceptibility to NGS Genetic DNA Test gene ICAM1 |
| Test Details |
The ICAM1 gene is involved in the immune response and plays a role in various diseases, including malaria. Malaria is a mosquito-borne infectious disease caused by the Plasmodium parasite. It primarily affects red blood cells and can lead to severe complications, including cerebral malaria. Cerebral malaria is a severe form of the disease that affects the brain and can result in coma, seizures, and death. The ICAM1 gene has been found to be associated with susceptibility to cerebral malaria. Variations in this gene can affect the expression or function of ICAM1, potentially influencing the immune response to the Plasmodium parasite and the development of cerebral malaria. NGS (Next-Generation Sequencing) genetic testing is a powerful tool used to analyze an individual’s DNA sequence. It can identify variations or mutations in specific genes, including ICAM1, that may contribute to disease susceptibility or other health conditions. By analyzing the ICAM1 gene using NGS, researchers can determine if certain variations are present that may increase or decrease the risk of developing cerebral malaria. NGS genetic testing for ICAM1 gene variants associated with malaria susceptibility can provide valuable information for understanding an individual’s risk of developing cerebral malaria. This information can be used to guide preventive measures, such as mosquito bite prevention strategies or targeted interventions, to reduce the risk of developing severe complications from malaria. It is important to note that genetic testing for malaria susceptibility is not typically performed as a routine diagnostic test. It is primarily used in research settings to study the genetic factors underlying disease susceptibility and to develop new strategies for prevention and treatment. |
